IMP enters the final stretch before its May 14 Q1 earnings with a clear internal tension: the stock is up 40% in a month, yet every senior officer sold shares the moment a new award cycle completed in early April.
The insider activity is the sharpest signal this week. On April 7, CEO and Chairman Patrick Blott sold 109,066 shares at CAD 1.72 — pocketing roughly CAD 187,500 — immediately after receiving an award of 118,908 shares. CFO Jennifer Bakken sold 67,306 shares at the same price. COO Jeremy Schneider and two independent directors followed the same pattern: receive the award, sell a portion the same day. The net 90-day insider position is technically positive at just over one million shares, but that reflects the scale of the award grants rather than open-market buying conviction. No insider reached into their own pocket to add shares.
The backdrop for those sales matters. Q4 2025 results — reported on April 1 — showed revenue collapsing to CAD 1.6 million from CAD 7.4 million a year earlier, with EPS swinging from +$0.04 to -$0.06. The stock nonetheless jumped roughly 9–11% on the day and held those gains through the week. That reaction, combined with the announcement that Intermap's AI flood risk platform had been adopted across the Czech insurance market, appears to have driven the subsequent rally. Investors appear to be pricing in a rebound narrative rather than the trailing fundamentals.
The lending market reflects a stock that is genuinely hard to borrow. Availability has tightened sharply — the borrow pool is nearly fully drawn, with utilization at 89.8% and approaching its 52-week peak of 90.2%. Cost to borrow has climbed to 7.45% annualised, up roughly 16% on the week, the highest level of the past month. Short interest itself is very low in absolute terms — under 0.2% of free float — so the tight availability does not point to a crowded short thesis. It more likely reflects thin float and concentrated ownership, which leaves the lending market vulnerable to squeezes on even modest demand. The ORTEX short score of 48.4 is broadly neutral and has been steady for two weeks, consistent with neither aggressive shorting nor a rapid unwind.
The one analyst covering the stock carries a buy rating with a mean price target of CAD 2.87 — about 47% above the current CAD 1.95 close. That data is roughly four weeks old and should be read with caution given the sharp price move since early March; the target may not yet reflect the full rally. The analyst recommendation differential ranks in the 93rd percentile of the universe, meaning the lone analyst is more bullish than almost all comparable coverage. Days-to-cover ranks in the 3rd percentile — essentially no meaningful short position to cover — which removes one potential overhang but also one potential source of buying pressure if sentiment shifts.
The largest registered holder, Blott himself, holds 8.8% of shares. Matco Financial added nearly 395,000 shares as of December year-end; Empire Life and NewGen both initiated positions then. Institutional interest from Canadian managers is real but concentrated and recent — several of the names appear for the first time in the December reporting round, suggesting the rally attracted fresh money into what remains a micro-cap name with thin liquidity.
The next fixed point is the May 14 earnings release. The two most recent prints each produced single-day moves of 9–11%, so the market has been reactive to these results. What Q1 reveals about the Czech insurance contract and any new pipeline wins will determine whether the rebound thesis — now embedded in a 40% price gain — has fundamental support or remains a sentiment trade on better days ahead.
See the live data behind this article on ORTEX.
Open IMP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
